Literature DB >> 33002259

Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.

Patrick Bodilly Kane1, Daniel M Benjamin2, Roger A Barker3, Anthony E Lang4, Todd Sherer5, Jonathan Kimmelman1.   

Abstract

BACKGROUND: Commentators suggest that patients have unrealistic expectations about the pace of research advances and that such expectations interfere with patient decision-making.
OBJECTIVE: The objective of this study was to compare expert expectations about the timing of research milestone attainment with those of patients who follow Parkinson's disease (PD) research.
METHODS: Patients with PD and experts were asked to provide forecasts about 11 milestones in PD research in an online survey. PD experts were identified from a Michael J. Fox Foundation database, highly ranked neurology centers in the United States and Canada, and corresponding authors of articles on PD in top medical journals. Patients with PD were recruited through the Michael J. Fox Foundation. We tested whether patient forecasts differed on average from expert forecasts. We also tested whether differences between patient forecasts and the average expert forecasts were associated with any demographic factors.
RESULTS: A total of 256 patients and 249 PD experts completed the survey. For 9 of the 11 milestones, patients' forecasts were on average higher than those of experts. Only exercise therapy met our 10% difference threshold for practical significance. Education was the only demographic that predicted patient deviations from expert forecasts on milestone forecasts. Patients offered significantly higher forecasts than experts that the clinical trials used in milestone queries would report positive primary outcomes.
CONCLUSIONS: Differences between patient and expert expectations about research milestones were generally minor, suggesting that there is little cause for concern that patients who follow PD research are unduly swayed by inaccurate representations of research advancement in the media or elsewhere.
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; prediction; forecasting

Mesh:

Year:  2020        PMID: 33002259      PMCID: PMC7891331          DOI: 10.1002/mds.28319

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  20 in total

Review 1.  Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine.

Authors:  Darren Lau; Ubaka Ogbogu; Benjamin Taylor; Tania Stafinski; Devidas Menon; Timothy Caulfield
Journal:  Cell Stem Cell       Date:  2008-12-04       Impact factor: 24.633

2.  In Defense of "Denial": Difficulty Knowing When Beliefs Are Unrealistic and Whether Unrealistic Beliefs Are Bad.

Authors:  J S Blumenthal-Barby; Peter A Ubel
Journal:  Am J Bioeth       Date:  2018-09       Impact factor: 11.229

3.  Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials.

Authors:  Rebecca D Pentz; Margaret White; R Donald Harvey; Zachary Luke Farmer; Yuan Liu; Colleen Lewis; Olga Dashevskaya; Taofeek Owonikoko; Fadlo R Khuri
Journal:  Cancer       Date:  2012-01-31       Impact factor: 6.860

4.  "I Want to Do It, But I Want to Make Sure That I Do It Right." Views of Patients with Parkinson's Disease Regarding Early Stem Cell Clinical Trial Participation.

Authors:  Inmaculada de Melo-Martín; Michael Holtzman; Katrina S Hacker
Journal:  AJOB Empir Bioeth       Date:  2020-06-09

5.  'Not taken in by media hype': how potential donors, recipients and members of the general public perceive stem cell research.

Authors:  V L Peddie; M Porter; C Counsell; L Caie; D Pearson; S Bhattacharya
Journal:  Hum Reprod       Date:  2009-01-24       Impact factor: 6.918

6.  "Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials.

Authors:  Shelly Benjaminy; Ian Macdonald; Tania Bubela
Journal:  Genet Med       Date:  2013-09-26       Impact factor: 8.822

7.  Nationwide Survey of Patient Knowledge and Attitudes towards Human Experimentation Using Stem Cells or Bee Venom Acupuncture for Parkinson's Disease.

Authors:  Sun Ju Chung; Seong Beom Koh; Young-Su Ju; Jae Woo Kim
Journal:  J Mov Disord       Date:  2014-10-30

8.  Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials.

Authors:  Emmi Reijula; Anna-Maija Pietilä; Arja Halkoaho; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

9.  Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

Authors:  Aden C Feustel; Amanda MacPherson; Dean A Fergusson; Karl Kieburtz; Jonathan Kimmelman
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

10.  Sociology of Low Expectations: Recalibration as Innovation Work in Biomedicine.

Authors:  John Gardner; Gabrielle Samuel; Clare Williams
Journal:  Sci Technol Human Values       Date:  2015-11
View more
  2 in total

1.  Relationship between lay and expert perceptions of COVID-19 vaccine development timelines in Canada and USA.

Authors:  Patrick Bodilly Kane; Hannah Moyer; Amanda MacPherson; Jesse Papenburg; Brian J Ward; Stephen B Broomell; Jonathan Kimmleman
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

2.  Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson's Disease?

Authors:  Michelle H S Tosin; Tanya Simuni; Glenn T Stebbins; Jesse M Cedarbaum
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.